Study on the Efficacy of Pemafibrate in Patients with Dyslipidemia ~A Study of the Efficacy of Apo B48 in Improving~ A Multicenter, Open-Label, Randomized, Parallel Group Study (PROUD48) Sub-analysis

Study on the Efficacy of Pemafibrate in Patients with Dyslipidemia ~A Study of the Efficacy of Apo B48 in Improving~ A Multicenter, Open-Label, Randomized, Parallel Group Study (PROUD48) Sub-analysis - PROUD48 Sub-analysis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056102

Enrollment

129

Registered

2024-11-08

Start date

2024-10-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects who participated in the PROUD48 study (*For validation using residual specimens, patients with sufficient blood sample volume for measurement of various items will be included)

Exclusion criteria

Exclusion criteria: Patients who have indicated their refusal by opting out Patients who do not have blood samples on file at the time of evaluation Principal Investigator

Design outcomes

Primary

Measure	Time frame
Cholesterol uptake capacity of HDL at 16 weeks	—

Secondary

Measure	Time frame
FABP1, FABP4, FABP5, FABP6, PCSK9, IL-1beta, IL-6, hs-CRP, sTNF-R1, sTNF-R2, EphA2, DLL4, GDF15, adiponectin, FGF21, TSK, PCSK7, TfR1, ACE2,ANGPTL3,ANGPTL4,ANGPTL8,T-Cadherin change, percent change	—

Countries

Japan

Contacts

Public ContactShinya Hiramitsu

Hiramitsu Heart Clinic Cardiology Department

hirazy@fujita-hu.ac.jp052-811-0383

Outcome results